Recombinant human OX40 / TNFRSF4 / CD134 Protein, Fc Tag, 100µg

Background
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

Source
Recombinant Human TNFRSF4 /OX40 /CD134 Protein, Fc Tag (OX0-H5255) is expressed from human 293 cells (HEK293). It contains AA Leu 29 - Ala 216 (Accession # NP_003318).
Predicted N-terminus: Leu 29

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 46.8 kDa. The protein migrates as 50-67 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Nonylphenol exacerbates ovalbumin-induced allergic rhinitis via the TSLP-TSLPR/IL-7R pathway and JAK1/2-STAT3 signaling in a mouse model"
Wang, Cao, Zhao et al
Ecotoxicol Environ Saf (2022) 243, 114005
(2) "Road testing new CAR design strategies in multiple myeloma"
Rana, Murphy, Kort et al
Front Immunol (2022) 13, 957157
(3) "Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects"
Cortellino, Raveane, Chiodoni et al
Cell Rep (2022) 40 (8), 111256
Showing 1-3 of 1847 papers.

Citations

(1) "Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist"
Authors: Upadhyaya P, Lahdenranta J, Hurov K, et al.
Journal: Journal for immunotherapy of cancer 2021
Application: SPR
(2) "ANTI-OX40 ANTIBODY AND USE THEREOF"
Authors: A T sun, et al
Journal: US20200140562A1 2020
Application: Flow cytometry